Alfen: Dead cat bounce? Ayvens: Overhang cure. Belgian telcos: Hey! discontinues €5 offer, OBEL price increases from June 2025. B&S Group: Pulls FY EBITDA guidance in light of tariffs. D'Ieteren: CMD, 1Q25 Preview. Kendrion: Wrestling through difficult macro conditions. NN Group, ASR: Vote on Dutch pension reforms postponed. TKH Group: Not that bad, good progress at Eemshaven. UCB: US Most Favoured Nation initiative back on the agenda. Vastned: Good results, integration ongoing...
A director at Next sold 100,000 shares at 12,362p and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Clo...
Die operative Trendwende hat sich mit Q4/24 – wie angekündigt - bestätigt und die 24er Guidance wurde erreicht. Die Q4-KPIs zeigen Umsatz- und EBITDA Margen-Erholung (Umsatz € 221 Mio./Marge: +12,98 %; EPS € -0,23), doch sind diese durch Phasing-Effekte und Reset-Einsparungen überzeichnet.
As announced, the operational turnaround was confirmed in Q4/24 and the FY24 guidance was achieved. The Q4 KPIs show revenue and EBITDA margin recovery (revenue € 221m/margin: +12.98%; EPS € -0.23), but these are overstated by phasing effects and reset savings.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.